Literature DB >> 7826821

The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly.

J R Dyer1, T M Davis, C Giele, T Annus, P Garcia-Webb, J Robson.   

Abstract

1. Quinine is a front-line antimalarial drug but is prescribed most commonly in nonmalarious countries for cramps. Postural hypotension, hearing loss and hyperinsulinaemic hypoglycaemia occur in malaria and overdose but little is known of quinine kinetics and toxicity in the elderly. 2. We studied 12 non-insulin-dependent diabetics and 10 non-diabetic controls aged 51-79 years. Subjects attended on two occasions > 7 days apart. On each test day, subjects were given a 600 Cal meal at 18.00 h (0 h) and, on one occasion, quinine sulphate 600 mg at 22.00 h (4 h). Venous blood samples for glucose, insulin and quinine assay were drawn pre-prandially and then regularly over the next 38 h. Supine and erect blood pressures were taken and audiometry was performed at 4, 6, 8 and 14 h. A one-compartment open pharmacokinetic model was fitted to serum quinine concentrations. 3. Absorption and elimination half-times, volume of distribution and oral clearance of quinine were comparable in the two groups (P > 0.2) and there was a mean absorption lag-time of approximately 1 h. Basal and immediate post-prandial (< 4 h) serum glucose and insulin concentrations on both test days were similar in the diabetics and also in the non-diabetics, but quinine produced a mean reduction in serum glucose of 1.0 mmol l-1 from 3-5 h post-dose in both groups without affecting serum insulin concentrations. Quinine administration did not alter postural blood pressure changes or produce significant hearing loss in either group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7826821      PMCID: PMC1364791          DOI: 10.1111/j.1365-2125.1994.tb04343.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  Glucose metabolism in quinine-treated patients with uncomplicated falciparum malaria.

Authors:  T M Davis; S Pukrittayakamee; W Supanaranond; S Looareesuwan; S Krishna; B Nagachinta; R C Turner; N J White
Journal:  Clin Endocrinol (Oxf)       Date:  1990-12       Impact factor: 3.478

2.  Glucose homeostasis in rats treated acutely and chronically with quinine.

Authors:  W Okitolonda; A M Pottier; J C Henquin
Journal:  Eur J Pharmacol       Date:  1986-12-16       Impact factor: 4.432

3.  Binding of quinine to plasma proteins in falciparum malaria.

Authors:  K Silamut; N J White; S Looareesuwan; D A Warrell
Journal:  Am J Trop Med Hyg       Date:  1985-07       Impact factor: 2.345

4.  Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: the importance of unbound quinine concentration.

Authors:  P Winstanley; C Newton; W Watkins; E Mberu; S Ward; P Warn; I Mwangi; C Waruiru; G Pasvol; D Warrell
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Mar-Apr       Impact factor: 2.184

5.  Effects of oral and parenteral quinine on rats with ventromedial hypothalamic knife-cut obesity.

Authors:  J Oku; G A Bray; J S Fisler
Journal:  Metabolism       Date:  1984-06       Impact factor: 8.694

Review 6.  Insulin secretion and insulin action in non-insulin-dependent diabetes mellitus: which defect is primary?

Authors:  G M Reaven
Journal:  Diabetes Care       Date:  1984 May-Jun       Impact factor: 19.112

7.  A quinine a day keeps the leg cramps away?

Authors:  A Warburton; J P Royston; C J O'Neill; P W Nicholson; R D Jee; M J Denham; S M Dobbs; R J Dobbs
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

8.  Quinine disposition kinetics.

Authors:  N J White; P Chanthavanich; S Krishna; C Bunch; K Silamut
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

9.  Severe hypoglycemia and hyperinsulinemia in falciparum malaria.

Authors:  N J White; D A Warrell; P Chanthavanich; S Looareesuwan; M J Warrell; S Krishna; D H Williamson; R C Turner
Journal:  N Engl J Med       Date:  1983-07-14       Impact factor: 91.245

10.  Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria.

Authors:  N J White; S Looareesuwan; D A Warrell; M J Warrell; D Bunnag; T Harinasuta
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

View more
  7 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Drug-induced disorders of glucose metabolism. Mechanisms and management.

Authors:  J C Chan; C S Cockram; J A Critchley
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 4.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

5.  A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition.

Authors:  X J Zhao; T Ishizaki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.569

6.  Glycemic effects of quinine infusion in healthy volunteers.

Authors:  Audrey Carine Njomatchoua; Aurel Tiakouang Tankeu; Eugene Sobngwi; Jean-Claude Mbanya
Journal:  BMC Res Notes       Date:  2017-08-24

7.  Clinical pharmacokinetics of quinine and its relationship with treatment outcomes in children, pregnant women, and elderly patients, with uncomplicated and complicated malaria: a systematic review.

Authors:  Teerachat Saeheng; Kesara Na-Bangchang
Journal:  Malar J       Date:  2022-02-10       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.